Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine

Transplantation

Volumn 79, Issue 9, 2005, Pages 1121-1127

  Wang, Hao ^a,b   Jiang, Jifu ^c   Liu, Weihua ^a,b   Kubelik, Dalibor ^b   Chen, Gang ^c   Gies, David ^d   Garcia, Bertha ^b   Zhong, Robert ^a,b,c,e   Rother, Russell P ^d  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d ALEXION PHARMACEUTICALS   (United States)

^e London Health Sciences Centre University Campus ^*  (Canada)

Author keywords

Acute vascular rejection; Allotransplantation; Anti C5 mAb; Complement

Indexed keywords

COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE VASCULAR REJECTION; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLEEDING; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MEGADOSE; GRAFT SURVIVAL; HEART GRAFT; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; VASCULITIS;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD VESSELS; COMPLEMENT C5; CYCLOSPORINE; FLOW CYTOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; ISOANTIBODIES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; TRANSPLANTATION, HOMOLOGOUS;

EID: 18544413129     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000161218.58276.9A     Document Type: Conference Paper

References (26)

1. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38(6 Suppl 6): S25.
2. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001; 71(5): 652.
3. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11(6): 609.
4. Platt JL, Saadi S. The role of complement in transplantation. Mol Immunol 1999; 36(13-14): 965.
5. Pratt JR, Hibbs MJ, Laver AJ, et al. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996; 149(6): 2055.
6. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 1991; 50(4): 350.
7. Forbes RD, Pinto-Blonde M, Guttmann RD. The effect of anticomplementary cobra venom factor on hyperacute rat cardiac allograft rejection. Lab Invest 1978; 39(5): 463.
8. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8(6): 582.
9. Qian Z, Wasowska BA, Behrens E, et al. C6 produced by macrophages contributes to cardiac allograft rejection. Am J Pathol 1999; 155(4); 1293.
10. Jose PJ, Forrest MJ, Williams TJ. Detection of the complement fragment C5a in inflammatory exudates from the rabbit peritoneal cavity using radioimmunoassay. J Exp Med 1983; 158(6): 2177.
11. Saadi S, Holzknecht RA, Patte CP, et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182(6): 1807.
12. Papadimitriou JC, Ramm LE, Drachenberg CB, et al. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol 1991; 147(1): 212.
13. Liszewski KM. In: Paul WE, ed. Fundamental immunology. New York, Raven 1993, p. 917.
14. Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition, with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60(11): 1194.
15. Wang H, Rollins SA, Gao Z, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999; 68(11): 1643.
16. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16(4): 343.
17. Wang H, Hosiawa KA, Min W, et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol 2003; 171(7): 3823.
18. Wang H, DeVries ME, Deng S, et al. The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection. Nat Med 2000; 6(5): 549.
19. Yin D, Ma L, Varghese A, et al. Intact active bone transplantation synergizes with anti-CD40 ligand therapy to induce B cell tolerance. J Immunol 2002; 168(10): 5352.
20. Baldwin WM III, Larsen CP, Fairchild RL. Innate immune responses to transplants: a significant variable with cadaver donors. Immunity 2001; 14(4): 369.
21. Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991; 12(9): 338.
22. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97(6): 1525.
23. Kilgore KS, Flory CM, Miller BF, et al. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149(3): 953.
24. Wrenshall LE, Cerra FB, Singh RK, et al. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. J Immunol 1995; 154(2): 871.
25. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97(22): 2259.
26. Shernan SK, Fitch JC, Nussmeier NA, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004; 77(3): 942.